|
Giulio F. Paciotti, Ph.D. - Co-founder and Vice President for Research and Development. Dr. Paciotti made the seminal discovery on the use of colloidal gold nanoparticles for developing tumor-targeted nanotherapeutics and is the principal inventor of the CytImmune’s diagnostic and therapeutic technologies. His work transitioned CytImmune’s core mission from diagnostics to therapeutics and is the cornerstone of CytImmune’s therapeutic research program. Dr. Paciotti’s work culminated in the development of the company’s first nanotherapeutic: Aurimune - a colloidal gold nanoparticle that targets the delivery of TNF to solid tumors. He directed the technology from the concept and R&D stages through clinical filings including GLP testing, cGMP manufacturing, and IND submission. Currently, he heads the company’s new therapeutic and collaborative efforts. Patents submitted and patents granted describe the use of the colloidal gold nanoparticle platform for developing new tumor-targeting nanotherapeutics, synthetic immune cells for the in vitro generation of human monoclonal antibodies, and targeted/multifunctional colloidal gold-based nanodrugs. Prior to establishing CytImmune’s therapeutic program Dr. Paciotti developed and patented the company’s diagnostic technology (Accucyte) for the detection of cytokines in biologic fluids. Dr. Paciotti received his B.S., M.S., and Ph.D. from the University of Maryland at College Park. | 